DE69942810D1 - Modifizierter Hitzeschockprotein-Antigenpeptid-Komplex - Google Patents
Modifizierter Hitzeschockprotein-Antigenpeptid-KomplexInfo
- Publication number
- DE69942810D1 DE69942810D1 DE69942810T DE69942810T DE69942810D1 DE 69942810 D1 DE69942810 D1 DE 69942810D1 DE 69942810 T DE69942810 T DE 69942810T DE 69942810 T DE69942810 T DE 69942810T DE 69942810 D1 DE69942810 D1 DE 69942810D1
- Authority
- DE
- Germany
- Prior art keywords
- complexes
- heat shock
- modified heat
- immunogenic
- shock protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6043—Heat shock proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7535898P | 1998-02-20 | 1998-02-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69942810D1 true DE69942810D1 (de) | 2010-11-11 |
Family
ID=22125179
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69935781T Expired - Lifetime DE69935781T2 (de) | 1998-02-20 | 1999-02-19 | Modifizierter hitzeschockprotein/peptidantigen komplex |
DE69942810T Expired - Lifetime DE69942810D1 (de) | 1998-02-20 | 1999-02-19 | Modifizierter Hitzeschockprotein-Antigenpeptid-Komplex |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69935781T Expired - Lifetime DE69935781T2 (de) | 1998-02-20 | 1999-02-19 | Modifizierter hitzeschockprotein/peptidantigen komplex |
Country Status (10)
Country | Link |
---|---|
US (2) | US8685384B2 (de) |
EP (3) | EP1054683B1 (de) |
JP (2) | JP4768122B2 (de) |
AT (2) | ATE482714T1 (de) |
AU (1) | AU757600B2 (de) |
CA (1) | CA2321101C (de) |
DE (2) | DE69935781T2 (de) |
DK (2) | DK1829551T3 (de) |
ES (3) | ES2285832T3 (de) |
WO (1) | WO1999042121A1 (de) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6331299B1 (en) | 1995-08-18 | 2001-12-18 | Sloan-Kettering Institute For Cancer Research | Method for treatment of cancer and infectious disease and compositions useful in same |
US6761892B1 (en) | 1995-08-18 | 2004-07-13 | Sloan-Kettering Institute For Cancer Research | Heat shock protein-based vaccines and immunotherapies |
CA2229595A1 (en) | 1995-08-18 | 1997-02-27 | Sloan-Kettering Institute For Cancer Research | Method for treatment of cancer and infectious diseases and compositions useful in same |
DE69935781T2 (de) * | 1998-02-20 | 2007-12-27 | University Of Miami, Miami | Modifizierter hitzeschockprotein/peptidantigen komplex |
US6495360B1 (en) * | 1999-05-28 | 2002-12-17 | Photogen, Inc. | Method for enhanced protein stabilization and for production of cell lines useful for production of such stabilized proteins |
AUPQ233799A0 (en) | 1999-08-19 | 1999-09-09 | Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales | Recombinant sub-unit vaccine |
US8128922B2 (en) | 1999-10-20 | 2012-03-06 | Johns Hopkins University | Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen |
US6846653B2 (en) | 2000-10-10 | 2005-01-25 | Genencor International, Inc. | Enhanced secretion of a polypeptide by a microorganism |
CA2460396A1 (en) | 2001-10-01 | 2003-04-10 | Duke University | Isolated grp94 ligand binding domain polypeptide and nucleic acid encoding same, crystalline form of same, and screening methods employing same |
JP4632664B2 (ja) * | 2002-02-13 | 2011-02-16 | デューク ユニバーシティ | 非ペプチド結合ストレス応答性ポリペプチドによる免疫応答の調節 |
US7420037B2 (en) | 2003-02-13 | 2008-09-02 | Antigenics Inc. | Heat shock protein-based vaccines and immunotherapies |
US7309491B2 (en) | 2003-04-11 | 2007-12-18 | Antigenics Inc. | Heat shock protein-based vaccines and immunotherapies |
EP1619208B1 (de) * | 2003-04-28 | 2008-10-29 | Sekisui Chemical Co., Ltd. | Komplex aus chaperonin und targetprotein, verfahren zu dessen herstellung, verfahren zur stabilisierung des targetproteins, verfahren zur immobilisierung des targetproteins, verfahren zur analyse der struktur des targetproteins, zubereitung mit retardierter freisetzung und verfahren zur herstellung von antikörpern gegen das targetprotein |
WO2004098526A2 (en) | 2003-05-05 | 2004-11-18 | Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein |
CA2594040A1 (en) | 2005-01-06 | 2006-07-13 | The Johns Hopkins University | Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines |
US9085638B2 (en) | 2007-03-07 | 2015-07-21 | The Johns Hopkins University | DNA vaccine enhancement with MHC class II activators |
ITPD20070252A1 (it) * | 2007-07-24 | 2009-01-25 | Primiero Paolo | Complessi di grp94 ed immunoglobuline g umane |
CA2717854C (en) * | 2008-03-03 | 2019-02-19 | The University Of Miami | Allogeneic cancer cell-based immunotherapy |
JP2011515399A (ja) * | 2008-03-20 | 2011-05-19 | ユニバーシティー オブ マイアミ | 熱ショックタンパクgp96ワクチン接種及びそれを用いた方法 |
WO2009155936A1 (en) | 2008-06-26 | 2009-12-30 | Orphazyme Aps | Use of hsp70 as a regulator of enzymatic activity |
CA2781197A1 (en) * | 2008-11-21 | 2010-05-27 | University Of Miami | Hiv/siv vaccines for the generation of mucosal and systemic immunity |
RU2011144575A (ru) | 2009-04-03 | 2013-05-10 | Эйдженус Инк. | Способы получения и применения мультишаперон-антигенных комплексов |
JP2013544263A (ja) | 2010-11-30 | 2013-12-12 | オルファザイム エーピーエス | Hsp70の細胞内活性を上昇させる方法 |
CN109608550B (zh) * | 2012-12-05 | 2020-09-11 | 生控基因疫苗股份有限公司 | 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白 |
HUE054957T2 (hu) | 2014-09-15 | 2021-10-28 | Orphazyme As | Arimoklomol készítése |
CN107208099B (zh) | 2015-02-06 | 2022-05-13 | 热生物制品有限公司 | 共表达疫苗和共刺激分子的载体 |
US10898476B2 (en) | 2016-04-13 | 2021-01-26 | Orphazyme A/S | Heat shock proteins and cholesterol homeostasis |
HUE052158T2 (hu) | 2016-04-29 | 2021-04-28 | Orphazyme As | Arimoklomol a glükocerebroszidázzal társult rendellenességek kezeléséhez |
US11666649B2 (en) | 2016-10-11 | 2023-06-06 | University Of Miami | Vectors and vaccine cells for immunity against Zika virus |
CA3058938A1 (en) | 2017-04-04 | 2018-10-11 | Heat Biologics, Inc. | Intratumoral vaccination |
AU2018378201A1 (en) * | 2017-12-04 | 2020-05-21 | Heat Biologics, Inc. | Production of cell-based vaccines |
KR20230128462A (ko) | 2020-11-19 | 2023-09-05 | 제브라 덴마크 에이/에스 | 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정 |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US5217891A (en) * | 1987-07-28 | 1993-06-08 | Chiron Corporation | DNA constructs containing a kluyveromyces α factor leader sequence for directing secretion of heterologous polypeptides |
DE68924162T2 (de) | 1988-06-15 | 1996-04-25 | Whitehead Biomedical Inst | Stressproteine und verwendungen dafür. |
US5137819A (en) | 1988-07-08 | 1992-08-11 | University Of British Columbia | Cellulose binding fusion proteins for immobilization and purification of polypeptides |
WO1990002564A1 (en) | 1988-09-12 | 1990-03-22 | Codon | Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi |
US5232833A (en) | 1988-09-14 | 1993-08-03 | Stressgen Biotechnologies Corporation | Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
WO1991002077A1 (en) | 1989-07-28 | 1991-02-21 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Efficient directional genetic cloning system |
GB9007194D0 (en) | 1990-03-30 | 1990-05-30 | Wellcome Found | Live vaccines |
US5348945A (en) | 1990-04-06 | 1994-09-20 | Wake Forest University | Method of treatment with hsp70 |
US5188964A (en) | 1990-04-12 | 1993-02-23 | Board Of Regents, The University Of Texas System | Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination |
GB9016315D0 (en) | 1990-07-25 | 1990-09-12 | Burnie James P | Medicaments |
ATE154759T1 (de) | 1990-11-08 | 1997-07-15 | Univ London | Mycobacterium als adjuvans für antigene |
GB9024320D0 (en) | 1990-11-08 | 1990-12-19 | Univ London | Treatment of uveitis |
GB2251186A (en) | 1990-12-04 | 1992-07-01 | Randall Neal Gatz | Polypeptide for use in treatment of autoimmune disease |
GB9200949D0 (en) | 1992-01-17 | 1992-03-11 | Medical Res Council | Diagnostic peptides |
FR2688227A1 (fr) | 1992-03-04 | 1993-09-10 | Inst Nat Sante Rech Med | Proteines formant des complexes avec des chaperones et leurs ligands, leurs fragments, leur obtention et leurs applications biologiques. |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
CA2130089A1 (en) | 1992-03-09 | 1993-09-16 | Aldo Mancini | Protein compound, coding nucleotide sequences, producing cell line and uses thereof |
JPH07505719A (ja) | 1992-04-14 | 1995-06-22 | デューク・ユニバーシティー | p53及びHSP70のコンプレックスを含む腫瘍の検出方法 |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
WO1994003599A1 (en) | 1992-08-04 | 1994-02-17 | Sagami Chemical Research Center | HUMAN cDNA AND PROTEIN WHICH SAID cDNA CODES FOR |
GB2270076A (en) | 1992-08-18 | 1994-03-02 | Univ Manchester | Human HSP 90 Epitopes |
GB9223816D0 (en) * | 1992-11-13 | 1993-01-06 | Medical Res Council | Heat shock proteins and the treatment of tumours |
CN1119459A (zh) | 1993-03-19 | 1996-03-27 | 柏伦格-英格尔海姆国际股份公司 | 肿瘤疫苗的制备方法 |
US5496934A (en) | 1993-04-14 | 1996-03-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nucleic acids encoding a cellulose binding domain |
WO1995004824A1 (en) | 1993-08-05 | 1995-02-16 | Medvet Science Pty. Ltd. | Generation of dna libraries and retroviral vectors for same |
US5705159A (en) | 1993-08-31 | 1998-01-06 | John Wayne Cancer Institute | Immunoreactive peptide sequence from a 43 KD human cancer antigen |
US5750119A (en) | 1994-01-13 | 1998-05-12 | Mount Sinai School Of Medicine Of The City University Of New York | Immunotherapeutic stress protein-peptide complexes against cancer |
US5997873A (en) | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
US5961979A (en) | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
WO1996001611A1 (en) * | 1994-07-08 | 1996-01-25 | Baxter International Inc. | Implanted device containing tumor cells for the treatment of cancer |
US5772995A (en) * | 1994-07-18 | 1998-06-30 | Sidney Kimmel Cancer Center | Compositions and methods for enhanced tumor cell immunity in vivo |
EP1016418B1 (de) | 1994-10-03 | 2009-12-30 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Wirtszelle enthaltend ein rekombinantes Virus, welches ein Antigen exprimiert und ein rekombinantes Virus, welches ein immunstimulatorisches Molekül exprimiert |
US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
US6331299B1 (en) | 1995-08-18 | 2001-12-18 | Sloan-Kettering Institute For Cancer Research | Method for treatment of cancer and infectious disease and compositions useful in same |
US6719974B1 (en) | 1995-08-18 | 2004-04-13 | Sloan-Kettering Institute For Cancer Research | Heat shock protein-based vaccines and immunotherapies |
CA2229595A1 (en) | 1995-08-18 | 1997-02-27 | Sloan-Kettering Institute For Cancer Research | Method for treatment of cancer and infectious diseases and compositions useful in same |
US6761892B1 (en) | 1995-08-18 | 2004-07-13 | Sloan-Kettering Institute For Cancer Research | Heat shock protein-based vaccines and immunotherapies |
US5985270A (en) | 1995-09-13 | 1999-11-16 | Fordham University | Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes |
US5935576A (en) | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
AU727673B2 (en) | 1995-09-13 | 2000-12-21 | Fordham University | Therapeutic and prophylactic methods using heat shock proteins |
US5837251A (en) | 1995-09-13 | 1998-11-17 | Fordham University | Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases |
WO1997026910A2 (de) | 1996-01-27 | 1997-07-31 | Max-Delbrück-Centrum für Molekulare Medizin | Tumorimpfstoff für die immuntherapie von malignen tumoren |
DE19602985A1 (de) | 1996-01-27 | 1997-07-31 | Max Delbrueck Centrum | Tumorzellimpfstoff für die Immuntheraphie von malignen Tumoren |
WO1997035619A1 (en) | 1996-03-28 | 1997-10-02 | Genitrix, L.L.C. | Opsonin-enhanced cells, and methods of modulating an immune response to an antigen |
US5747332A (en) | 1996-09-20 | 1998-05-05 | University Of New Mexico | Methods for purifying and synthesizing heat shock protein complexes |
US6130087A (en) | 1996-10-07 | 2000-10-10 | Fordham University | Methods for generating cytotoxic T cells in vitro |
CA2272536A1 (en) | 1996-11-26 | 1998-06-04 | Stressgen Biotechnologies Corp. | Immune responses using compositions containing stress proteins |
US5830464A (en) | 1997-02-07 | 1998-11-03 | Fordham University | Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy |
US6017540A (en) | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
US6007821A (en) * | 1997-10-16 | 1999-12-28 | Fordham University | Method and compositions for the treatment of autoimmune disease using heat shock proteins |
US5948646A (en) | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
DE69935781T2 (de) | 1998-02-20 | 2007-12-27 | University Of Miami, Miami | Modifizierter hitzeschockprotein/peptidantigen komplex |
US6797480B1 (en) | 1998-10-05 | 2004-09-28 | University Of Connecticut Health Center | Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents |
US6451316B1 (en) | 1998-10-05 | 2002-09-17 | University Of Conneticut Health Center | Methods for generating antigen-reactive T cells in vitro |
US6475490B1 (en) | 1998-10-19 | 2002-11-05 | Fordham University | Compositions and methods for promoting tissue repair using heat shock proteins |
US7132109B1 (en) | 2000-10-20 | 2006-11-07 | University Of Connecticut Health Center | Using heat shock proteins to increase immune response |
WO2003005964A2 (en) | 2001-07-11 | 2003-01-23 | University Of Miami | Recombinant vsv for the treatment of tumor cells |
WO2003053338A2 (en) | 2001-11-16 | 2003-07-03 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services | Novel chimeric rev, tat, and nef antigens |
WO2003063801A2 (en) | 2002-02-01 | 2003-08-07 | Thomas Jefferson University | Treatment of tumor cells for use in immunotherapy of cancer |
CA2501744C (en) | 2002-10-09 | 2012-01-03 | Central Iowa Health System | Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase |
WO2005030136A2 (en) | 2003-09-26 | 2005-04-07 | University Of Miami | Tumor vaccine |
CA2537340A1 (en) | 2003-09-26 | 2005-04-07 | Applied Research Systems Ars Holding N.V. | Leader sequences for use in production of proteins |
FR2867982B1 (fr) | 2004-03-26 | 2007-07-20 | Jean Marie Andrieu | Procede pour amplifier l'activite de vaccins therapeutiques |
WO2006123256A2 (en) | 2005-02-24 | 2006-11-23 | Medical Research Council | Hivcon: an hiv immunogen and uses thereof |
CA2717854C (en) | 2008-03-03 | 2019-02-19 | The University Of Miami | Allogeneic cancer cell-based immunotherapy |
JP2011515399A (ja) | 2008-03-20 | 2011-05-19 | ユニバーシティー オブ マイアミ | 熱ショックタンパクgp96ワクチン接種及びそれを用いた方法 |
CA2781197A1 (en) | 2008-11-21 | 2010-05-27 | University Of Miami | Hiv/siv vaccines for the generation of mucosal and systemic immunity |
-
1999
- 1999-02-19 DE DE69935781T patent/DE69935781T2/de not_active Expired - Lifetime
- 1999-02-19 DK DK07007299.6T patent/DK1829551T3/da active
- 1999-02-19 AT AT07007299T patent/ATE482714T1/de not_active IP Right Cessation
- 1999-02-19 EP EP99908252A patent/EP1054683B1/de not_active Expired - Lifetime
- 1999-02-19 DK DK10011076.6T patent/DK2295065T3/da active
- 1999-02-19 ES ES99908252T patent/ES2285832T3/es not_active Expired - Lifetime
- 1999-02-19 CA CA2321101A patent/CA2321101C/en not_active Expired - Fee Related
- 1999-02-19 ES ES07007299T patent/ES2355483T3/es not_active Expired - Lifetime
- 1999-02-19 AU AU27731/99A patent/AU757600B2/en not_active Ceased
- 1999-02-19 EP EP07007299A patent/EP1829551B1/de not_active Expired - Lifetime
- 1999-02-19 ES ES10011076.6T patent/ES2439014T3/es not_active Expired - Lifetime
- 1999-02-19 AT AT99908252T patent/ATE359084T1/de not_active IP Right Cessation
- 1999-02-19 WO PCT/US1999/003561 patent/WO1999042121A1/en active IP Right Grant
- 1999-02-19 EP EP10011076.6A patent/EP2295065B1/de not_active Expired - Lifetime
- 1999-02-19 JP JP2000532135A patent/JP4768122B2/ja not_active Expired - Fee Related
- 1999-02-19 DE DE69942810T patent/DE69942810D1/de not_active Expired - Lifetime
-
2007
- 2007-07-24 US US11/878,460 patent/US8685384B2/en not_active Expired - Lifetime
-
2010
- 2010-09-22 JP JP2010212423A patent/JP5518659B2/ja not_active Expired - Fee Related
-
2014
- 2014-02-11 US US14/178,204 patent/US20140335086A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DK1829551T3 (da) | 2011-01-24 |
EP1829551A1 (de) | 2007-09-05 |
JP2011001378A (ja) | 2011-01-06 |
WO1999042121A1 (en) | 1999-08-26 |
ATE359084T1 (de) | 2007-05-15 |
EP1054683B1 (de) | 2007-04-11 |
EP1829551B1 (de) | 2010-09-29 |
US20140335086A1 (en) | 2014-11-13 |
US20080026012A1 (en) | 2008-01-31 |
EP2295065A1 (de) | 2011-03-16 |
DE69935781T2 (de) | 2007-12-27 |
US8685384B2 (en) | 2014-04-01 |
JP5518659B2 (ja) | 2014-06-11 |
EP2295065B1 (de) | 2013-10-09 |
ATE482714T1 (de) | 2010-10-15 |
CA2321101C (en) | 2014-12-09 |
AU757600B2 (en) | 2003-02-27 |
DK2295065T3 (da) | 2014-01-06 |
CA2321101A1 (en) | 1999-08-26 |
JP4768122B2 (ja) | 2011-09-07 |
AU2773199A (en) | 1999-09-06 |
ES2355483T3 (es) | 2011-03-28 |
JP2002506005A (ja) | 2002-02-26 |
ES2439014T3 (es) | 2014-01-21 |
EP1054683A4 (de) | 2004-12-29 |
DE69935781D1 (de) | 2007-05-24 |
ES2285832T3 (es) | 2007-11-16 |
EP1054683A1 (de) | 2000-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE359084T1 (de) | Modifizierter hitzeschockprotein/peptidantigen komplex | |
JP2011516070A5 (de) | ||
JP2007516696A5 (de) | ||
JP2002512800A5 (de) | ||
EP1015009A4 (de) | abgeschwächte VIF DNA Immunisierungscassetten als genetische Impfstoffe | |
KR890700030A (ko) | 인플루엔자균(Haemophilus influenzae)의 백신 및 진단방법 | |
WO2002074920A3 (en) | A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same | |
CN104131022A (zh) | 产气荚膜梭菌α、β1、β2、ε毒素共表达载体及其构建方法和表达方法 | |
DE3585578D1 (de) | Hepatitisoberflaechenantigenpartikelvakzin. | |
AU3379693A (en) | Vaccines and diagnostic assays for haemophilus influenzae | |
IE870507L (en) | Bovine virus diarrhea and hog cholera vaccines | |
SE8105516L (sv) | Syntetisk dna och forfarande for framstellning derav | |
DK1334197T3 (da) | Gær-afledt vaccine mod IPNV | |
US20020081304A1 (en) | Type f botulinum toxin and use thereof | |
DE69021886D1 (de) | Äusseres membranprotein p1 und peptide von haemophilus influenzae typ b. | |
JP2656098B2 (ja) | 可溶性両親媒性タンパク質ならびにその製造および精製法 | |
EP0789563B8 (de) | Impfstoffe gegen den hepatitis b und c virus | |
CN114853912B (zh) | 一种牛病毒性腹泻病毒e2-e0融合蛋白、制备方法及应用 | |
CN104744594B (zh) | 乙肝病毒多表位与志贺毒素的融合蛋白及其制备方法和应用 | |
RU2702716C2 (ru) | Рекомбинантная плазмида pHis6-flagG-protE, обеспечивающая синтез рекомбинантного химерного белка, включающего эпитопы гликопротеина Е вируса клещевого энцефалита и флагеллин G S.typhii и используемого в качестве основы для вакцины против вируса клещевого энцефалита | |
Bandehpour et al. | Cloning and expression of Hepatitis B surface antigen | |
CA2370278A1 (en) | Chimeric lyssavirus nucleic acids and polypeptides | |
CN102286068A (zh) | 一种狂犬病毒疫苗增效蛋白及编码该蛋白的基因和应用 | |
DE60100879D1 (de) | Helicobacter felis Impfstoff | |
CN101244269A (zh) | 一种重组口蹄疫病毒融合蛋白疫苗 |